# US 2012/0252695 A1 · Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers alone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252695 A1
- Document ID: US20120252695A1
- Status: Published application
- Kind: A1
- Application number: 13/514,193
- Filed: 2010-12-21
- Published: 2012-10-04
- Earliest claimed: 2009-12-22
- Assignees: Janssen R&D Ireland
- Inventors: Jeroen Aerssens; Gregory Charles Fanning; Michael W. Fried
- Web page: https://patentgrep.com/patent/US20120252695A1

## CPC

- C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.

## Claims

### Claim 1

Method of combining two or more parameters selected from the group consisting of the pre-treatment serum level measurement of IP-10, the IL28B genotype determination, race or Hepatitis C viral load determination to predict the outcome of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.

### Claim 2 (depends on 1)

Method according to claim 1 wherein said IL28B genotype determination with said pre-treatment serum level measurement of IP-10 is combined to predict the outcome of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.

### Claim 3 (depends on 2)

Method according to claim 2 wherein the race parameter is added.

### Claim 4 (depends on 2)

Method according to claim 2 wherein the Hepatitis C viral load determination is added.

### Claim 5 (depends on 2)

Method according to claim 2 wherein the race parameter and the Hepatitis C viral load determination are added.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Method according to any of the claims 1-5 wherein the IL28B genotype comprises the polymorphic marker rs12979860, rs12980275 and/or rs8099917, or any other genetic marker that is in linkage disequilibrium with these markers.

### Claim 7 (depends on 6)

Method according to claim 6 wherein the combination measurement further discriminates between SVR and non-response to peginterferon and ribavirin for an individual patient infected with HCV, in comparison with any of these two individual markers (IL28B genotype, serum IP-10 level).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

Diagnostic assay for use in the method according to any of the claims 1-7 comprising means for at least the determination or measurement of IL28B polymorphism and IP-10 levels in serum from an HCV-infected patient.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

Computer system comprising modeling software using the outcome information obtained from the method of any of the claims 1-7 for the prediction of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.
